Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Contineum Therapeutics, Inc. (CTNM : NSDQ)

• Company Description    Contineum Therapeutics Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies which target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications with high unmet need. The company's product pipeline includes PIPE-791 and PIPE-307. Contineum Therapeutics Inc. is based in SAN DIEGO. Number of Employees: 51

• Price / Volume Information    Yesterday's Closing Price: $13.86 Daily Weekly Monthly 20 Day Moving Average: 190,585 shares Shares Outstanding: 37.39 (millions) Market Capitalization: $518.17 (millions) Beta: 0.89 52 Week High: $16.33 52 Week Low: $3.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.59% 6.14% 12 Week -12.17% -18.80% Year To Date 21.26% 15.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3565 GENERAL ATOMICS COURT SUITE 200 - SAN DIEGO,CA 92121 USA ph: 858-333-5280 fax: - ir@contineum-tx.com http://www.contineum-tx.com

• General Corporate Information    Officers Carmine Stengone - Chief Executive Officer; Presidentt and Director Evert Schimmelpennink - Chairperson of the Board of Directors Peter Slover - Chief Financial Officer Lori Lyons-Williams - Director Diego Miralles - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 21217B100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 37.39 Most Recent Split Date: (:1) Beta: 0.89 Market Capitalization: $518.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.79 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.07 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 37.10% vs. Previous Quarter: 20.41% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -27.09 12/31/25 - -30.08 09/30/25 - -32.33 ROA 03/31/26 - -25.64 12/31/25 - -28.27 09/30/25 - -30.27 Current Ratio 03/31/26 - 38.00 12/31/25 - 27.50 09/30/25 - 29.07 Quick Ratio 03/31/26 - 38.00 12/31/25 - 27.50 09/30/25 - 29.07 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 6.69 12/31/25 - 6.99 09/30/25 - 6.18 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©